APTO

Aptose Biosciences
APTO

$0.89
2.68%
 

About: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Employees: 36

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

4% less funds holding

Funds holding: 28 [Q4 2023] → 27 (-1) [Q1 2024]

10.07% less ownership

Funds ownership: 16.51% [Q4 2023] → 6.44% (-10.07%) [Q1 2024]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

49% less capital invested

Capital invested by funds: $3.33M [Q4 2023] → $1.68M (-$1.65M) [Q1 2024]

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
462%
upside
Avg. target
$9.2
934%
upside
High target
$23
2,484%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
687%upside
$7
Buy
Reiterated
14 Jun 2024
Canaccord Genuity
John Newman
574%upside
$6
Buy
Maintained
16 May 2024
Piper Sandler
Edward Tenthoff
462%upside
$5
Overweight
Maintained
3 Apr 2024
HC Wainwright & Co.
Joseph Pantginis
2,484%upside
$23
Buy
Maintained
27 Mar 2024
Piper Sandler
Edward Tenthoff
462%upside
$5
Overweight
Maintained
1 Feb 2024

Financial journalist opinion

Based on 4 articles about APTO published over the past 30 days